Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx-M in HBV-Related HCC
NCT03899415Phase 1Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liocyx-m in hepatocellular carcinoma (HCC), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Incidences of adverse events/serious adverse events. Status: unknown.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03899415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899415.